# XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)

Source: https://onco.cc/trials/nct07381777/  
OnCo record `nct07381777` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cAPOX (capecitabine, oxaliplatin) and dostarlimab in colorectal cancer, run by Gruppo Oncologico Italiano di Ricerca Clinica, not yet recruiting.

## Summary

XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients is a phase 2, randomised interventional study registered as NCT07381777 by Gruppo Oncologico Italiano di Ricerca Clinica, with a registry enrolment figure of 270 participants, started 2026-01-31 and due to reach its primary completion in 2028-07-01. Interventions recorded: XELOX (Capecitabine and Oxaliplatin); Dostarlimab. Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: Clinical complete response (cCR) at 12 months. Colorectal eligibility wording from the registry: "* Histologically proven rectal adenocarcinoma with distal extension less 16 cm from the anal verge". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: IMMUNOSTAR
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07381777
- Phase: 2
- Setting: Phase II Randomized Trial of XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients - IMMUNOSTAR Trial GOIRC-02-2024
- Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT07381777: https://clinicaltrials.gov/study/NCT07381777

## Connected records

- cancers: [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07381777.json